Skip to main content Skip to search Skip to main navigation

Swissmedic: Swiss GMDP database in early 2024

According to Swissmedic, the independent SwissGMDP database will be launched in the first quarter of 2024. The database will be maintained similar to the European EudraGMDP database of the EMA. The GMP or GDP certificates of every company in Switzerland that has a valid Swissmedic operating licence will be listed. Contrary to the EudraGMDP, the SwissGMDP certificates contain all approved activities, i.e. the GDP activities and Switzerland-specific GMP activities of the Swiss companies will also be listed in the certificates.

The GMP/GDP status of a company should be easily accessible to all companies, authorities and persons via the portal. Furthermore, SwissGMDP enables a retrieval of all licence holders with a valid operating licence, including their locations and approved activities, and will replace the previous list of licence holders.

Summarised, the SwissGMDP database will:

  • be accessible to the general public,
  • provide free access to electronic GMP/GDP certificates
  • also include Switzerland-specific activities
  • allow access to GDP certificates of companies with only GDP related activities in their licences,
  • improve the exchange of information between regulators and the public, including the pharmaceutical industry,
  • contribute to the protection of the drug distribution chain and the active ingredient supply chain by facilitating the verification of legitimate operators,
  • greatly reduce the expenses of most companies for the issuance of GMP/GDP certificates, as all GMP/GDP certificates are available free of charge.

To maintain the SwissGMDP database, there will be a small fee for each application- or inspection-driven update of the GMP/GDP-relevant data. The database is expected to go live on the Swissmedic website in the first quarter of 2024. The exact date will be announced in due time.


Source:

Swissmedic: SwissGMDP Database

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

News: EMA

EMA Clarifies Batch Numbering for Parallel-Traded Medicines

EMA updated its GMP/GDP Q&A collection by revising the answer to Question 4 concerning Chapter 5 of the EU GMP Guide. It explains which batch numbers should appear on the packaging of parallel-traded medicines.

Read more
Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Robust PDE reports form the basis of risk-based cleaning validation. This article highlights common deficiencies identified during GMP inspections and explains how they can be avoided.

Read more
Question of the Week | GMP-Verlag

Why is it Important to use Consistent Microbiological Air Monitoring Methods in Pharmaceutical Cleanrooms?

Here's the answer:
Read more
News: Europe

EDQM: New Working Party on 3D-printed Medicinal Products

The European Pharmacopoeia Commission (EPC) approved the creation of a working party on 3D-printed medicinal products. Its aim is to support the development of appropriate quality standards in the European Pharmacopoeia (Ph. Eur.).
Read more
EMA: 14 New Nitrosamines for Appendix 1

EMA: 14 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO published a revised draft of its “WHO guidelines on quality risk management”. Working document QAS/26.994 is open for public comment until 15 November 2026.
Read more
Previous
Next